Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII Report on one case and review of other uses in acute leukemias

Basit Öğe Kaydı
dc.contributor.authorPamuk, Guelsuem Emel
dc.contributor.authorTasci, Murat
dc.contributor.authorOzturk, Erman
dc.contributor.authorDemir, Muzaffer
dc.date.accessioned2024-06-12T10:50:34Z
dc.date.available2024-06-12T10:50:34Z
dc.date.issued2010
dc.departmentTrakya Üniversitesien_US
dc.description.abstractHemorrhage is a frequent complication in patients with acute leukemias as a result of chemotherapy-induced myelosuppression. Gastrointestinal bleeding in thrombocytopenic patients carries a high mortality. Patients are generally managed with red blood cell, platelet suspensions, and fresh frozen plasma; and sometimes with pharmacologic and endoscopic interventions. If these therapeutic measures fail, patients might be treated with hemostatic drugs, one example of which is recombinant activated factor VII (rFVIIa). This drug is recommended for all kinds of bleeding in hemophiliacs with inhibitors; it is also being used for the treatment of bleeding in thrombocytopenia and platelet function disorders. We present our 44-year-old female patient who had gastrointestinal system bleeding after remission induction therapy for acute myeloid leukemia. Thrombocytopenia was refractory to apheresis platelets; and gastrointestinal bleeding could be controlled only after the administration of a single dose (35 mu g/kg, total dose 2.4 mg) of rFVIIa. Our experience indicates that rFVIIa might be a novel treatment alternative in massive bleeding in leukemic patients with thrombocytopenia or platelet function disorders.en_US
dc.identifier.doi10.1007/s12032-008-9163-y
dc.identifier.endpage19en_US
dc.identifier.issn1357-0560
dc.identifier.issue1en_US
dc.identifier.pmid19137431en_US
dc.identifier.scopus2-s2.0-77949269590en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage16en_US
dc.identifier.urihttps://doi.org/10.1007/s12032-008-9163-y
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18055
dc.identifier.volume27en_US
dc.identifier.wosWOS:000273748800003en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherHumana Press Incen_US
dc.relation.ispartofMedical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcute Myeloid Leukemiaen_US
dc.subjectGastrointestinal Bleedingen_US
dc.subjectRecombinant Activated Factor VII (Rfviia)en_US
dc.subjectThrombocytopeniaen_US
dc.subjectAcute Myeloid-Leukemiaen_US
dc.subjectDiffuse Alveolar Hemorrhageen_US
dc.subjectPatienten_US
dc.subjectNovoseven(R)en_US
dc.subjectMechanismen_US
dc.subjectManagementen_US
dc.subjectInhibitorsen_US
dc.subjectRfviiaen_US
dc.titleSuccessful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII Report on one case and review of other uses in acute leukemiasen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu